Fine Tuning the Management of HCC: Strategies for Improving Patient Care - El Segundo

Hematology-Oncology
Curriculum:
HEP020
Credits:
1.5 AMA PRA Category 1 Credit(s)™
Launch Date:
July 17, 2013
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

The intended audience for this activity includes oncologists, hepatologists, gastroenterologists, radiation oncologists, surgical oncologists, pathologists, and other clinicians involved in the treatment of patients with HCC.

Relevant Terms:

Liver Cancer

 Ghassan Abou-Alfa, MD

Ghassan Abou-Alfa, MD
Associate Professor
Memorial Sloan-Kettering Cancer Center
New York, New York

Dr Abou-Alfa is a board-certified medical oncologist treating patients with gastrointestinal cancers. He completed his fellowship training at Yale School of Medicine and joined the faculty of Memorial Sloan-Kettering in 2001. Since that time he has been an active investigator testing new targeted therapies in clinical studies and advocating for greater awareness of liver disease's global inpact.

Karen T. Brown, MD, FSIR 

Karen T. Brown, MD, FSIR
Associate Professor
Memorial Sloan-Kettering Cancer Center
New York, New York

Dr Brown has been practicing Interventional Radiology since 1985. She attended the University of Michigan as an undergraduate, Boston University School of Medicine for her medical degree, began a surgical residency at Emory University and completed a radiology residency at Massachusetts General Hospital. Dr. Brown finished her training in Vascular Radiology at Massachusetts General Hospital in 1985 and began her career at St. Luke's Roosevelt Hospital, where her primary interest was in peripheral vascular intervention, in NYC in 1985.
 
She moved to Memorial Sloan-Kettering Cancer Center in 1992 where, as an Interventional Oncologist, her primary areas of interest became the diagnosis and treatment of hepatocellular carcinoma (HCC). She was awarded an NIH grant in 2007 to study treatment response after trans-arterial embolization with unloaded microspheres compared with doxorubicin loaded microspheres. That study was successfully completed and data analysis is ongoing. Dr Brown is known nationally and internationally for her work, has given over 70 invited lectures here & abroad, has authored over 90 peer-reviewed articles and written 10 book chapters.
1. Discuss the disease burden of hepatocellular carcinoma (HCC) and surveillance strategies 
2. Identify the different staging and scoring systems used in HCC
3. Describe personalized, targeted therapy for the treatment of patients with HCC to optimize clinical outcomes 
4. Demonstrate the management of treatment-related side effects in patients with HCC 
5. Describe strategies to enhance the multidisciplinary approach for the management of HCC 
6. Counsel appropriately selected patients with HCC about the availability of and participation in ongoing clinical trials 

Estimated time to complete activity: 1.5 hours

Release date: Wednesday, July 17, 2013 | Expiration date: Friday, August 30, 2013
 
TARGET AUDIENCE
The target audience for this activity includes oncologists, hepatologists, gastroenterologists, radiation oncologists, surgical oncologists, pathologists, and other clinicians involved in the treatment of patients with HCC.
 
DESIGNATION OF CREDIT
PHYSICIAN CONTINUING EDUCATION 
Accreditation Statement 

Educational Concepts Group, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. 

Credit Designation Statement 
Educational Concepts Group, LLC designates this live material for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this activity. During the period Wednesday, July 17, 2013 through Friday, August 30, 2013, participants must 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the post-activity assessment.
 
CME CREDIT
Physicians who complete the post-activity assessment may view and print their credit letter.
 
POLICY ON DISCLOSURE
It is the policy of ECG that the faculty, authors, planners, and other persons who may influence content of this CME activity disclose all relevant financial relationships with commercial interests in order to allow ECG to identify and resolve any potential conflicts of interest.
 
The Following Faculty Members Have Declared Relevant Financial Relationships
Ghassan Abou-Alfa, MD
Grants/Research Support
Abbott Laboratories, Amgen Inc., Bayer HealthCare Pharmaceuticals, Inc., Genentech, Inc., ImClone Systems, Novartis, Polaris Pharmaceuticals, Inc., Roche 
 
Spouse
Abbott Laboratories, Agensys Inc., Astellas Pharma US, Inc., AstraZeneca, Momenta Pharmaceuticals, Inc., OncoMed Pharmaceuticals, Inc., sanofi-aventis
 
Consultant Fees
Abbott Laboratories, Amgen Inc., ArQule, Bayer HealthCare Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Celsion Corporation, Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo, Inc., Exelixis, Inc., Genentech, Inc., ImClone Systems, Jennerex Biotherapeutics, Inc., Novartis, Polaris Pharmaceuticals, Inc., Roche, Vicus Therapeutics
 
Spouse
Celgene Corporation, Clovis Oncology, Gilead Sciences, Inc., Merck & Co., Inc., Momenta Pharmaceuticals, Inc., Novartis, OSI Pharmaceuticals, Inc., Piramal Pharma Solutions, Polaris Pharmaceuticals, Inc., Roche, sanofi-aventis, ZIOPHARM Oncology, Inc.
  
Karen T. Brown, MD, FSIR
No relevant financial relationships to disclose

Staff Disclosure
Planners and managers at ECG have no relevant financial relationships to disclose.
 
DISCLOSURE OF OFF-LABEL USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. ECG does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity do not necessarily represent the views of ECG. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. 

 
Please refer to the official prescribing information for each product or consult the Physicians' Desk Reference for discussion of approved indications, contraindications, and warnings. 

ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
This activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals, Inc./Onyx Pharmaceuticals, Inc. 
 
CME INQUIRIES
For further information, please contact:
Educational Concepts Group, LLC 
1300 Parkwood Circle SE, Suite 325
Atlanta, Georgia 30339
Phone: 1.866.933.1681
www.educationalconcepts.net

This activity is sponsored by Educational Concepts Group, LLC
 

This activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals, Inc./Onyx Pharmaceuticals, Inc.